JP2018537418A5 - - Google Patents

Download PDF

Info

Publication number
JP2018537418A5
JP2018537418A5 JP2018519903A JP2018519903A JP2018537418A5 JP 2018537418 A5 JP2018537418 A5 JP 2018537418A5 JP 2018519903 A JP2018519903 A JP 2018519903A JP 2018519903 A JP2018519903 A JP 2018519903A JP 2018537418 A5 JP2018537418 A5 JP 2018537418A5
Authority
JP
Japan
Prior art keywords
seq
patient
pharmaceutical composition
immunoglobulin
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018519903A
Other languages
English (en)
Japanese (ja)
Other versions
JP6858766B2 (ja
JP2018537418A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/056166 external-priority patent/WO2017068472A1/en
Publication of JP2018537418A publication Critical patent/JP2018537418A/ja
Publication of JP2018537418A5 publication Critical patent/JP2018537418A5/ja
Priority to JP2021048873A priority Critical patent/JP7389077B2/ja
Application granted granted Critical
Publication of JP6858766B2 publication Critical patent/JP6858766B2/ja
Priority to JP2023116721A priority patent/JP2023134701A/ja
Priority to JP2025168405A priority patent/JP2026010006A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018519903A 2015-10-19 2016-10-14 インターロイキン17(il−17)アンタゴニストを用いてx線陰性体軸性脊椎関節炎を治療する方法 Active JP6858766B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021048873A JP7389077B2 (ja) 2015-10-19 2021-03-23 インターロイキン17(il-17)アンタゴニストを用いてx線陰性体軸性脊椎関節炎を治療する方法
JP2023116721A JP2023134701A (ja) 2015-10-19 2023-07-18 インターロイキン17(il-17)アンタゴニストを用いてx線陰性体軸性脊椎関節炎を治療する方法
JP2025168405A JP2026010006A (ja) 2015-10-19 2025-10-06 インターロイキン17(il-17)アンタゴニストを用いてx線陰性体軸性脊椎関節炎を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562243381P 2015-10-19 2015-10-19
US62/243,381 2015-10-19
PCT/IB2016/056166 WO2017068472A1 (en) 2015-10-19 2016-10-14 Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021048873A Division JP7389077B2 (ja) 2015-10-19 2021-03-23 インターロイキン17(il-17)アンタゴニストを用いてx線陰性体軸性脊椎関節炎を治療する方法

Publications (3)

Publication Number Publication Date
JP2018537418A JP2018537418A (ja) 2018-12-20
JP2018537418A5 true JP2018537418A5 (https=) 2019-09-12
JP6858766B2 JP6858766B2 (ja) 2021-04-14

Family

ID=57223732

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018519903A Active JP6858766B2 (ja) 2015-10-19 2016-10-14 インターロイキン17(il−17)アンタゴニストを用いてx線陰性体軸性脊椎関節炎を治療する方法
JP2021048873A Active JP7389077B2 (ja) 2015-10-19 2021-03-23 インターロイキン17(il-17)アンタゴニストを用いてx線陰性体軸性脊椎関節炎を治療する方法
JP2023116721A Withdrawn JP2023134701A (ja) 2015-10-19 2023-07-18 インターロイキン17(il-17)アンタゴニストを用いてx線陰性体軸性脊椎関節炎を治療する方法
JP2025168405A Pending JP2026010006A (ja) 2015-10-19 2025-10-06 インターロイキン17(il-17)アンタゴニストを用いてx線陰性体軸性脊椎関節炎を治療する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021048873A Active JP7389077B2 (ja) 2015-10-19 2021-03-23 インターロイキン17(il-17)アンタゴニストを用いてx線陰性体軸性脊椎関節炎を治療する方法
JP2023116721A Withdrawn JP2023134701A (ja) 2015-10-19 2023-07-18 インターロイキン17(il-17)アンタゴニストを用いてx線陰性体軸性脊椎関節炎を治療する方法
JP2025168405A Pending JP2026010006A (ja) 2015-10-19 2025-10-06 インターロイキン17(il-17)アンタゴニストを用いてx線陰性体軸性脊椎関節炎を治療する方法

Country Status (11)

Country Link
US (2) US20190330328A1 (https=)
EP (1) EP3365011A1 (https=)
JP (4) JP6858766B2 (https=)
KR (1) KR20180064415A (https=)
CN (1) CN108367074A (https=)
AU (4) AU2016342578A1 (https=)
CA (1) CA3002622A1 (https=)
HK (1) HK1251481A1 (https=)
IL (2) IL257723B2 (https=)
RU (2) RU2728710C2 (https=)
WO (1) WO2017068472A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103154031A (zh) 2010-10-08 2013-06-12 诺华有限公司 利用il-17拮抗剂治疗牛皮癣的方法
BR112013011176A2 (pt) 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CA3002622A1 (en) * 2015-10-19 2017-04-27 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
CN116059350A (zh) 2015-10-27 2023-05-05 Ucb生物制药有限责任公司 使用抗-il-17a/f抗体的治疗方法
US11299540B2 (en) 2017-06-18 2022-04-12 Kindred Biosciences, Inc. IL17A antibodies and antagonists for veterinary use
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
EP4591879A3 (en) 2019-01-31 2025-10-22 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
EP3963541A1 (en) * 2019-04-29 2022-03-09 UCB Biopharma SRL Medical image analysis system and method for identification of lesions
TW202126329A (zh) * 2019-09-20 2021-07-16 瑞士商諾華公司 使用白細胞介素-17(il-17)拮抗劑治療自體免疫性疾病之方法
US20240012009A1 (en) * 2020-11-05 2024-01-11 Keyintel Medical Inc. Methods for systematically assessing local inflammation and active repair
EP4471427A1 (en) * 2023-05-31 2024-12-04 Centre Hospitalier Universitaire De Nice Biomarker for spondyloarthitis diagnostic and response to treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
BRPI0706788A2 (pt) 2006-01-31 2011-04-05 Novartis Ag anticorpos antagonistas il-17
BR112013011176A2 (pt) * 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
WO2013158821A2 (en) * 2012-04-20 2013-10-24 Novartis Ag Methods of treating ankylosing spondylitis using il-17 antagonists
CA3002622A1 (en) * 2015-10-19 2017-04-27 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists

Similar Documents

Publication Publication Date Title
JP2018537418A5 (https=)
Sieper et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials
Van der Heijde et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
JP7389077B2 (ja) インターロイキン17(il-17)アンタゴニストを用いてx線陰性体軸性脊椎関節炎を治療する方法
CA2825986C (en) Arthritis treatment
US20220313818A1 (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritic patients
CN106413748A (zh) 用于类风湿性关节炎治疗的组合物及使用该组合物的方法
JP2022177132A (ja) 精神障害の治療
So et al. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis
RU2014117510A (ru) Лечение ревматоидного артрита
JP2015172060A5 (https=)
JP2022529929A5 (https=)
TW202126329A (zh) 使用白細胞介素-17(il-17)拮抗劑治療自體免疫性疾病之方法
Woodrick et al. IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.
Lourenço et al. Polymyalgia rheumatica after ChAdOx1 nCov-19 vaccine: a case report
Adelsten et al. Safe and effective tumour necrosis factor-α inhibitor (etanercept) treatment of chronic episodic arthritis in a patient with cystic fibrosis
TW202246329A (zh) 抗il-17抗體治療自體免疫性疾病和炎症的方法
Wiland et al. FRI0087 Efficacy, safety, and immunogenicity results of the switch from reference adalimumab (refadl) to Sandoz biosimilar adalimumab (gp2017, sdz-adl) from ADMYRA phase 3 study in patients with moderate-to-severe rheumatoid arthritis (RA)
CN115515978A (zh) 用于治疗呼吸系统疾病的pan-elr+cxc趋化因子抗体
TW202114734A (zh) Il-17拮抗劑治療自身免疫疾病的方法
Carolina et al. Polymyalgia Rheumatica After ChAdOx1 nCov-19 Vaccine: A Case Report
Walsh et al. O06 Improvements in pain, function and health status with subcutaneous tanezumab compared with placebo in patients with OA: pooled analysis of two randomized controlled trials
TW202540166A (zh) 用於治療自體免疫性疾病/自體免疫性病症的cd19選擇性t細胞接合分子
DATE et al. Ilaris (canakinumab) Policy Number: C2435-A
bt Solehan et al. Rheumatoid arthritis: refractory to infliximab, a tumor necrosis factor inhibitor